Drugs Made In America Acquisition DMIIR
NASDAQ DMIIR
$0.07 -0.01 (-7.04%)
As of: Sep 2, 2026 · 12:48 PM EDT

Drugs Made In America Acquisition (DMIIR) Income towards Parent Company (2025 - 2026)

Drugs Made In America Acquisition (DMIIR) posted quarterly Income towards Parent Company of $4.6 million for Q4 2025, up 10041.88% quarter-over-quarter from -$46158.0 in Q3 2025.

Analysis

Drugs Made In America Acquisition (DMIIR) Income towards Parent Company (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has reported Income towards Parent Company for 1 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Cluster Group Holdings 8.00 Bn 8.00 Bn -
2 Agriculture & Natural Solutions Acquisition 853.42 Mn 853.17 Mn -
3 K&F Growth Acquisition 836.15 Mn 836.15 Mn -
4 Armada Acquisition 666.50 Mn 666.45 Mn -
5 Pioneer Acquisition I 652.74 Mn 652.27 Mn -
6 Oxley Bridge Acquisition 652.11 Mn 652.11 Mn -
7 Titan Acquisition 651.43 Mn 941.85 Mn -
8 GSR IV Acquisition 622.22 Mn 622.22 Mn -
9 Launch One Acquisition 618.70 Mn 618.70 Mn -
10 Drugs Made In America Acquisition 5.10 Mn 5.10 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.40 Mn
Dec 31, 2025 4.59 Mn
Sep 30, 2025 -46,158.00